Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy

References

• National Cancer Institute. Chronic Myelogenous Leukemia Treatment (PDQ). US Department of Health and Human Services, 2015. Available at: http://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq#section/all [Last accessed 26 May 2015]
   Google Scholar
• Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;2006:240-5
   Google Scholar
• Novartis Pharmaceuticals Corporation. GLEEVEC (imatinib mesylate) tablets for oral use. US Food and Drug Administration, 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021588s042lbl.pdf [Last accessed 26 May 2015]
   Google Scholar
• Bristol-Myers Squibb Company. Sprycel Prescribing Information. US Food and Drug Administration, 2014. Available at: http://packageinserts.bms.com/pi/pi_sprycel.pdf [Last accessed 26 May 2015]
   Google Scholar
• Novartis Pharmaceutical Corp. Tasigna Prescribing Information. US Food and Drug Administration, 2015. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf [Last accessed 26 May 2015]
   Google Scholar
• Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:djv048
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al., eds. Leukemia, SEER Cancer Statistics Review, 1975–2011. Bethesda, MD, USA: National Cancer Institute, 2014. Available at: http://seer.cancer.gov/archive/csr/1975_2011/results_merged/sect_13_leukemia.pdf [Last accessed 26 May 2015]
   Google Scholar
• National Cancer Institute. Chronic Myeloid Leukemia – SEER Stat Fact Sheets. Bethesda, MD, USA: National Cancer Institute, 2015. Available at: http://seer.cancer.gov/statfacts/html/cmyl.html [Last accessed 26 May 2015]
   Google Scholar
• Gugliotta G, Castagnetti F, Apolinari M, et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 2014;74:627-43
   PubMed Web of Science ®Google Scholar
• Wu EQ, Yu AP, Guo A, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9
   PubMed Web of Science ®Google Scholar
• Trivedi D, Landsman-Blumberg P, Darkow T, et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Pharm 2014;20:1006-15
   PubMed Web of Science ®Google Scholar
• Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012;28:213-19
   PubMed Web of Science ®Google Scholar
• Guérin A, Chen L, Wu EQ, et al. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 2012;28:1155-62
   PubMed Web of Science ®Google Scholar
• Griffin JD, Guerin A, Chen L, et al. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis. Curr Med Res Opin 2013;29:623-31
   PubMed Web of Science ®Google Scholar
• Breccia M, Latagliata R, Stagno F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011;96:1457-61
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics (US). The International Classification of Diseases: 9th Revision, Clinical Modification: ICD-9-CM, 4th edn. Washington, DC, USA: US Department of Health and Human Services, Public Health Service, Health Care Financing Administration, 1991
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 1996;34:1093-101
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer Price Index (CPI). Washington, DC: US Bureau of Labor Statistics, 2014. Available at: http://www.bls.gov/cpi/[Last accessed 28 April 2014]
   Google Scholar
• Elixhauser A, Kruzikas D, Steiner C. Comorbidity Software Documentation. US Agency for Healthcare Research and Quality, 2004. Available at: http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp [Last accessed 18 August 2015]
   Google Scholar
• Coutre PD, Turkina A, Kim D, Ceglarek B. Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. In: Blood 2009:abstract 3286. Available at: https://ash.confex.com/ash/2009/webprogram/Paper19517.html
   Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors. Cancer 2011;117(5):897-906
   Google Scholar
• Korkmaz S, Dal MS, Berber I, et al. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: a retrospective multicenter study. Geriatr Gerontol Int 2014: published online 26 September 2014, doi: 10.1111/ggi.12341
   PubMed Web of Science ®Google Scholar
• Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program 2013;2013:168-75
   PubMed Web of Science ®Google Scholar
• Baccarani M, Castagnetti F, Gugliotta G, et al. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis 2014;6(1):e2014005
   Google Scholar
• Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514-20
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981-7
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar
• Kim TD, le Coutre P, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012;97:883-9
   PubMed Web of Science ®Google Scholar
• Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol 2015;90:E66-72
   PubMed Web of Science ®Google Scholar
• Stève-Dumont M, Baldin B, Legros L, et al. Are nilotinib-associated vascular adverse events an under-estimated problem? Fundam Clin Pharmacol 2015;29:204-8
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Chronic myelogenous leukemia, v1.2015. Fort Washington, PA: National Comprehensive Cancer Network (NCCN), 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf [Last accessed 26 May 2015]
   Google Scholar
• van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:e315-26
   PubMed Web of Science ®Google Scholar
• Latagliata R, Ferrero D, Iurlo A, et al. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging 2013;30:629-37
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011;25:147-57
   PubMed Web of Science ®Google Scholar
• La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013;92:1345-50
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, Kim D-W, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014;123:1309-18
   PubMed Web of Science ®Google Scholar
• Minasian L, Rosen O, Auclair D, et al. Optimizing dosing of oncology drugs. Clin Pharmacol Ther 2014;96:572-9
   PubMed Web of Science ®Google Scholar
• Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63:249-79
   PubMed Web of Science ®Google Scholar
• Russo D, Malagola M, Skert C, et al. Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era. Curr Cancer Drug Targets 2013;13:755-67
   PubMed Web of Science ®Google Scholar
• Hochhaus A. Optimizing tolerability of TKI therapy in CML. Blood 2014;123:1284-5
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 2009;84:161-9
   PubMed Web of Science ®Google Scholar
• Trask PC, Mitra D, Iyer S, et al. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol 2012;95:535-44
   PubMed Web of Science ®Google Scholar